Patterns of relapse after chemotherapy in patients with high-risk non-seminomatous germ cell tumor

Oncology

Volumn 78, Issue 1, 2010, Pages 47-53

  Oechsle, Karin ^a   Lorch, Anja ^b   Honecker, Friedemann ^a   Kollmannsberger, Christian ^e   Hartmann, Jörg T ^d   Boehlke, Ina ^a   Beyer, Jörg ^b,c   Bokemeyer, Carsten ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

^c VIVANTES KLINIKUM AM URBAN   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Computed tomography; Follow up procedures; Germ cell tumor; High dose chemotherapy; Relapse pattern; Serum tumor markers

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; IFOSFAMIDE; PACLITAXEL; TUMOR MARKER;

ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL EXAMINATION; CLINICAL FEATURE; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG MEGADOSE; FOLLOW UP; GERM CELL TUMOR; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; METASTASIS; MULTIPLE CYCLE TREATMENT; PATIENT MONITORING; PRIORITY JOURNAL; RADIODIAGNOSIS; RELAPSE; REMISSION; RETROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CISPLATIN; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GERM CELL AND EMBRYONAL; PLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77649310234     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000292358     Document Type: Article

References (11)

1. Bosl GJ, Motzer RJ: Medical progress: testicular germ-cell cancer. N Engl J Med 1997; 337: 242-253.
2. Einhorn LH: Curing metastatic testicular cancer. Proceedings of the National Academy of Sciences of the United States of America 2002; 99: 4592-4595.
3. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15: 594-603.
4. Huddart RA, Purkalne G, ESMO Guidelines Task Force: ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of mixed or non-seminomatous germ cell tumors (NSGCT). Ann Oncol 2005; 16: 37-39.
5. Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Cavallin-Ståhl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder PH, De Santis M, de Wit M, de Wit R, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, Fizazi K, Flechon A, Fosså SD, del Muro XG, Gauler T, Geczi L, Gerl A, Germa-Lluch JR, Gillessen S, Hartmann JT, Hartmann M, Heidenreich A, Hoeltl W, Horwich A, Huddart R, Jewett M, Joffe J, Jones WG, Kisbenedek L, Klepp O, Kliesch S, Koehrmann KU, Kollmannsberger C, Kuczyk M, Laguna P, Galvis OL, Loy V, Mason MD, Mead GM, Mueller R, Nichols C, Nicolai N, Oliver T, Ondrus D, Oosterhof GO, Paz-Ares L, Pizzocaro G, Pont J, Pottek T, Powles T, Rick O, Rosti G, Salvioni R, Scheiderbauer J, Schmelz HU, Schmidberger H, Schmoll HJ, Schrader M, Sedlmayer F, Skakkebaek NE, Sohaib A, Tjulandin S, Warde P, Weinknecht S, Weissbach L, Wittekind C, Winter E, Wood L, von der Maase H: European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol 2008 53: 497-513.
6. Schmoll HJ, Kollmannsberger C, Metzner B, Hartmann JT, Schleucher N, Schoffski P, Schleicher J, Rick O, Beyer J, Hossfeld D, Kanz L, Berdel WE, Andreesen R, Bokemeyer C; German Testicular Cancer Study Group: Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 2003; 21: 4083-4091.
7. Hartmann JT, Gauler T, Metzner B, Gerl A, Casper J, Rick O, Horger M, Schleicher J, Derigs G, Mayer-Steinacker R, Beyer J, Kuczyk MA, Bokemeyer C; German Testicular Cancer Study Group: Phase I/II study of sequential dose-intensified ifosfamide, cisplatin, and etoposide plus paclitaxel as induction chemotherapy for poor prognosis germ cell tumors by the German Testicular Cancer Study Group. J Clin Oncol 2007; 25: 5742-5747.
8. Lorch A, Kollmannsberger C, Hartmann JT, Metzner B, Schmidt-Wolf IG, Berdel WE, Weissinger F, Schleicher J, Egerer G, Haas A, Schirren R, Beyer J, Bokemeyer C, Rick O; German Testicular Cancer Study Group: Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group. J Clin Oncol 2007; 25: 2778-2784.
9. Flechon A, Culine S, Theodore C, Droz JP: Pattern of relapse after first line treatment of advanced stage germ-cell tumors. Eur Urol 2005; 48: 957-963.
10. Oechsle K, Kollmannsberger C, Honecker F, Boehlke I, Bokemeyer C: Cerebral metastases in non-seminomatous germ cell tumour patients undergoing primary high-dose chemotherapy. Eur J Cancer 2008; 44: 1663-1669.
11. Gietema JA, Meinradi MT, Sleijfer DT, Hoekstra HJ, van der Graaf WT: Routine chest Xrays have no additional value in the detection of relapse during routine follow-up of patients treated with chemotherapy for disseminated non-seminomatous testicular cancer. Ann Oncol 2002; 13: 1616-1620.